Kim Schrier sold Mesabi Trust (NYSE: MSB)
Kim Schrier (D-WA), a U.S. Representative, has disclosed 1 trade in Mesabi Trust (MSB) since 2021, a single sale, worth an estimated $8K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Kim Schrier sold $1,001 - $15,000 of Mesabi Trust (NYSE: MSB) on October 28, 2021. Since that trade, MSB is up +55.08% against the S&P 500 up +72.15%, an outperformance of -17.07%.
Data updated
Kim Schrier's MSB trades vs the price
MSB is up +55.08% since Kim Schrier sold on October 28, 2021, versus +72.15% for the S&P 500.
Performance since this trade
All Kim Schrier MSB trades
Kim Schrier & MSB trading FAQ
Is it legal for Kim Schrier to trade Mesabi Trust (MSB) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Mesabi Trust (MSB), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Kim Schrier sell MSB?
Kim Schrier disclosed a sale of $1,001 - $15,000 of Mesabi Trust (MSB) on October 28, 2021, according to public STOCK Act filings.
How has MSB performed since Kim Schrier's trade?
Since Kim Schrier sold MSB on October 28, 2021, the stock is up +55.08%, versus +72.15% for the S&P 500 over the same period, an outperformance of -17.07%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional MSB trades?
Quantellect tracks every disclosed congressional trade in Mesabi Trust (MSB) on the Mesabi Trust congressional trading page, which aggregates filings across all members of Congress.
Kim Schrier's MSB tradesAll congressional filings for Mesabi TrustKim Schrier's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.